LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Joseph Biederman, MD (1947-2023).

    Ceranoglu, Atilla / Doyle, Robert / Faraone, Stephen V / Geller, Daniel / Joshi, Gagan / Rubin, David / Spencer, Thomas / Surman, Craig / Uchida, Mai / Wilens, Timothy / Wozniak, Janet

    Journal of the American Academy of Child and Adolescent Psychiatry

    2023  

    Language English
    Publishing date 2023-05-16
    Publishing country United States
    Document type Journal Article
    ZDB-ID 392535-3
    ISSN 1527-5418 ; 0890-8567
    ISSN (online) 1527-5418
    ISSN 0890-8567
    DOI 10.1016/j.jaac.2023.05.008
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Um IV Zs.163: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: A Randomized, Double-Blind, Controlled Clinical Trial of Omega-3 Fatty Acids and Inositol as Monotherapies and in Combination for the Treatment of Pediatric Bipolar Spectrum Disorder in Children Age 5-12.

    Wozniak, Janet / Farrell, Abigail / DiSalvo, Maura / Ceranoglu, Atilla / Uchida, Mai / Vaudreuil, Carrie / Joshi, Gagan / Faraone, Stephen V / Cook, Emmaline / Biederman, Joseph

    Psychopharmacology bulletin

    2022  Volume 52, Issue 4, Page(s) 31–51

    Abstract: Objectives: The aim of this study was to assess the efficacy and tolerability of omega-3 fatty acids (FAs) and inositol alone and in combination for the treatment of pediatric bipolar (BP) spectrum disorder in young children.: Methods: Participants ... ...

    Abstract Objectives: The aim of this study was to assess the efficacy and tolerability of omega-3 fatty acids (FAs) and inositol alone and in combination for the treatment of pediatric bipolar (BP) spectrum disorder in young children.
    Methods: Participants were male and female children ages 5-12 meeting DSM-IV diagnostic criteria for a BP spectrum disorder and displaying mixed, manic, or hypomanic symptoms without psychotic features at the time of evaluation.
    Results: Participants concomitantly taking psychotropic medication were excluded from efficacy analyses. There were significant reductions in YMRS and HDRS mean scores in the inositol and combination treatment groups (all p < 0.05) and in CDRS mean scores in the combination treatment group (p < 0.001), with the largest changes seen in the combination group. Those receiving the combination treatment had the highest rates of antimanic and antidepressant response. The odds ratios for the combination group compared to the omega-3 FAs and inositol groups were clinically meaningful (ORs ≥2) for 50% improvement on the YMRS, normalization of the YMRS (score <12) (vs. inositol group only), 50% improvement on the HDRS, 50% improvement on CDRS (vs. omega-3 FAs group only), and CGI-I Mania, CGI-I MDD, and CGI-I Anxiety scores <2.
    Conclusion: The antimanic and antidepressant effects of the combination treatment of omega-3 FAs and inositol were consistently superior to either treatment used alone. This combination may offer a safe and effective alternative or augmenting treatment for youth with BP spectrum disorder, but more work is needed to confirm the statistical significance of this finding.
    MeSH term(s) Adolescent ; Male ; Child ; Humans ; Female ; Child, Preschool ; Bipolar Disorder/drug therapy ; Bipolar Disorder/diagnosis ; Antimanic Agents ; Antipsychotic Agents/therapeutic use ; Inositol/pharmacology ; Inositol/therapeutic use ; Psychiatric Status Rating Scales ; Double-Blind Method ; Antidepressive Agents/therapeutic use ; Fatty Acids, Omega-3/pharmacology ; Fatty Acids, Omega-3/therapeutic use ; Mania ; Treatment Outcome
    Chemical Substances Antimanic Agents ; Antipsychotic Agents ; Inositol (4L6452S749) ; Antidepressive Agents ; Fatty Acids, Omega-3
    Language English
    Publishing date 2022-11-08
    Publishing country United States
    Document type Randomized Controlled Trial ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 4113-0
    ISSN 2472-2448 ; 0048-5764 ; 0376-0162
    ISSN (online) 2472-2448
    ISSN 0048-5764 ; 0376-0162
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 958: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Does L-Methylfolate Supplement Methylphenidate Pharmacotherapy in Attention-Deficit/Hyperactivity Disorder?: Evidence of Lack of Benefit From a Double-Blind, Placebo-Controlled, Randomized Clinical Trial.

    Surman, Craig / Ceranoglu, Atilla / Vaudreuil, Carrie / Albright, Brittany / Uchida, Mai / Yule, Amy / Spencer, Andrea / Boland, Heidi / Grossman, Rebecca / Rhodewalt, Lauren / Fitzgerald, Maura / Biederman, Joseph

    Journal of clinical psychopharmacology

    2019  Volume 39, Issue 1, Page(s) 28–38

    Abstract: Purpose/background: Interventions for attention-deficit/hyperactivity disorder (ADHD) may be inadequate for some patients. There is evidence that supplementation with L-methylfolate augments antidepressant agent effects and thus might also augment ADHD ... ...

    Abstract Purpose/background: Interventions for attention-deficit/hyperactivity disorder (ADHD) may be inadequate for some patients. There is evidence that supplementation with L-methylfolate augments antidepressant agent effects and thus might also augment ADHD treatment effects by a common catecholaminergic mechanism.
    Methods: Forty-four adults with Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition diagnosis of ADHD participated in a randomized, double-blind, placebo-controlled, 12-week trial of 15 mg of L-methylfolate in combination with osmotic-release oral system methylphenidate. Osmotic-release oral system methylphenidate was dose optimized over the first 6 weeks. We evaluated the effects on ADHD symptoms, self-report on the Behavior Rating Inventory of Executive Function of executive function, methylphenidate dosing, neuropsychological test measures, the Adult ADHD Self-report scale, emotional dysregulation, social adjustment, and work productivity, as well as moderating effects of body mass index, autoantibodies to folate receptors, and select genetic polymorphisms.
    Results: L-Methylfolate was well tolerated, with no significant effect over placebo except improvement from abnormal measures on the mean adaptive dimension of the ASR scale (χ = 4.36, P = 0.04). Methylphenidate dosing was significantly higher in individuals on L-methylfolate over time (χ = 7.35, P = 0.007). Exploratory analyses suggested that variation in a guanosine triphosphate cyclohydrolase gene predicted association with higher doses of methylphenidate (P < 0.001).
    Conclusions: L-Methylfolate was associated with no change in efficacy on measures relevant to neuropsychiatric function in adults with ADHD, other than suggestion of reduced efficacy of methylphenidate. Further investigation would be required to confirm this effect and its mechanism and the genotype prediction of effects on dosing.
    MeSH term(s) Administration, Oral ; Adult ; Attention Deficit Disorder with Hyperactivity/drug therapy ; Attention Deficit Disorder with Hyperactivity/genetics ; Autoantibodies/blood ; Autoantibodies/immunology ; Central Nervous System Stimulants/therapeutic use ; Delayed-Action Preparations/therapeutic use ; Diet Therapy ; Dietary Supplements ; Dopamine Uptake Inhibitors/administration & dosage ; Dopamine Uptake Inhibitors/therapeutic use ; Dose-Response Relationship, Drug ; Double-Blind Method ; Drug Therapy, Combination ; Executive Function/drug effects ; Female ; Folate Receptor 1/immunology ; GTP Cyclohydrolase/genetics ; Humans ; Male ; Methylphenidate/administration & dosage ; Methylphenidate/therapeutic use ; Neuropsychological Tests ; Pilot Projects ; Tetrahydrofolates/adverse effects ; Tetrahydrofolates/therapeutic use ; Treatment Outcome ; Young Adult
    Chemical Substances Autoantibodies ; Central Nervous System Stimulants ; Delayed-Action Preparations ; Dopamine Uptake Inhibitors ; FOLR1 protein, human ; Folate Receptor 1 ; Tetrahydrofolates ; Methylphenidate (207ZZ9QZ49) ; GTP Cyclohydrolase (EC 3.5.4.16) ; 5-methyltetrahydrofolate (TYK22LML8F)
    Language English
    Publishing date 2019-01-07
    Publishing country United States
    Document type Journal Article ; Randomized Controlled Trial
    ZDB-ID 604631-9
    ISSN 1533-712X ; 0271-0749
    ISSN (online) 1533-712X
    ISSN 0271-0749
    DOI 10.1097/JCP.0000000000000990
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1664: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top